10-May-2024
NVAX, GRPN and MVIS among mid-day movers
Seeking Alpha News (Fri, 10-May 12:57 PM ET)
Novavax, Macrogenics, Biofrontera among healthcare movers
Seeking Alpha News (Fri, 10-May 10:00 AM ET)
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Benzinga (Fri, 10-May 9:23 AM ET)
Piper Sandler Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
TipRanks (Fri, 10-May 8:04 AM ET)
TipRanks (Fri, 10-May 7:00 AM ET)
TipRanks (Fri, 10-May 6:50 AM ET)
Revance Therapeutics GAAP EPS of -$0.58, revenue of $51.94M
Seeking Alpha News (Thu, 9-May 4:50 PM ET)
Revance Therapeutics Launches DAXXIFY® for Cervical Dystonia
TipRanks (Thu, 9-May 4:26 PM ET)
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Business Wire (Thu, 9-May 4:06 PM ET)
Business Wire (Thu, 9-May 4:05 PM ET)
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Revance Therapeutics trades on the NASDAQ stock market under the symbol RVNC.
As of May 10, 2024, RVNC stock price declined to $3.32 with 7,992,453 million shares trading.
RVNC has a beta of 1.56, meaning it tends to be more sensitive to market movements. RVNC has a correlation of 0.05 to the broad based SPY ETF.
RVNC has a market cap of $345.99 million. This is considered a Small Cap stock.
Last quarter Revance Therapeutics reported $52 million in Revenue and -$.54 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.21.
In the last 3 years, RVNC stock traded as high as $37.98 and as low as $3.00.
The top ETF exchange traded funds that RVNC belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
RVNC has underperformed the market in the last year with a price return of -90.8% while the SPY ETF gained +27.8%. RVNC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.8% and -2.4%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
RVNC support price is $4.09 and resistance is $4.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVNC stock will trade within this expected range on the day.